G. Kees Hovingh
Cleveland Clinic(US)Novo Nordisk (Denmark)(DK)Novo Nordisk (United Kingdom)(GB)Amsterdam University Medical Centers(NL)University of Amsterdam(NL)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, Lipid metabolism and disorders, Cholesterol and Lipid Metabolism
Most-Cited Works
- → Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes(2023)2,254 cited
- → Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management(2015)1,387 cited
- → Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity(2023)1,275 cited
- → Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society(2014)1,034 cited
- → HDL and cardiovascular disease(2014)853 cited
- → PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial(2014)